The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

详细信息    查看全文

• 作者：Justin Stebbing ; Thomas Powles ; Kirsty McPherson ; Jonathan Shamash ; Paula Wells ; Michael T. Sheaff ; Sarah Slater ; Robin M. Rudd ; Dean Fennell ; Jeremy P.C. Steele
• 关键词：Mesothelioma ; Relapsed ; Vinorelbine ; Second-line
• 刊名：Lung Cancer
• 出版年：2009
• 出版时间：January 2009
• 年：2009
• 卷：63
• 期：1
• 页码：94-97
• 全文大小：161 K

文摘

Summary

Malignant pleural mesothelioma (MPM) is a rapidly progressive invariably lethal tumor. Treatment options remain limited and the outcome in relapsed disease is poor warranting new therapeutic options. Following our previous experience in the first-line setting, we conducted a phase 2 open-label non-comparative study to assess the safety and efficacy of weekly vinorelbine chemotherapy, each cycle consisting of 30 mg/m² for 6 weeks, in patients with previous exposure to chemotherapy. In 63 individuals with relapsed MPM who had not received previous vinorelbine, we observed an objective response rate of 16 % and an overall survival of 9.6 months (95 % confidence interval 7.3–11.8 months). The main grade III/IV toxicity observed was neutropenia and toxicity was similar to weekly vinorelbine when used in the first-line setting. Weekly vinorelbine appeared to have a reasonable response rate with an acceptable toxicity profile in the second-line treatment of MPM. Its use should be prospectively evaluated in a randomised trial in the first or second-line therapy of MPM.